GERMAN OK CLEARS WAY FOR GREATER USE OF BASF EXCIPIENT

BASF's recently introduced polymer excipient, Kollicoat IR, has been granted its first registration in a finished drug product. The excipient has reached the market in a 1,000mg formulation of the diabetes medication metformin -- which is available in generic form but was originated by Merck KGaA -- in Germany. Germany will act as the rapporteur in for a European Union-wide approval of the product under a mutual recognition procedure. "This registration will help our European customers to increase the speed of future registrations for their products containing Kollicoat IR," said Dr Tim Bölke, director of strategic marketing pharma solutions at BASF.

In-PharmaTechnologist (http://www.in-pharmatechnologist.com/news/news-ng.asp?n=62571-basf-kollicoat-ir-excipient)